Skip to main content
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd. — Investor Relations & Filings

Ticker · 1099 ISIN · CNE100000FN7 LEI · 529900N54X78YH9JYK92 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,603 across all filing types
Latest filing 2025-10-27 Interim / Quarterly Rep…
Country CN China
Listing HKEX 1099

About Sinopharm Group Co. Ltd.

http://www.sinopharmholding.com

Sinopharm Group Co. Ltd. is a major state-owned enterprise recognized as the largest pharmaceutical logistics provider in Asia and a leading distributor and retailer of healthcare products. The company's core business revolves around providing comprehensive medical supply chain services, encompassing the wholesale and retail distribution of pharmaceuticals, medical devices, and general healthcare products. Sinopharm serves a broad customer base, including hospitals, primary health service institutions, and retail pharmacies. Furthermore, the Group maintains an integrated ecosystem that extends beyond distribution into the manufacturing of pharmaceuticals and chemical reagents, medical services, and industry-finance integration, positioning it as a full-spectrum service provider in the healthcare sector.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT QUARTERLY FINANCIAL INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025
Interim / Quarterly Report Classification · 100% confidence The document is a formal announcement by Sinopharm Group Co. Ltd. providing unaudited consolidated financial statements (balance sheet, income statement, and cash flow statement) for the nine-month period ended 30 September 2025. It is not a full annual report, but rather a comprehensive interim/quarterly financial disclosure required by the Shanghai Stock Exchange and the Hong Kong Stock Exchange. It contains substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-10-27 English
ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025
Earnings Release Classification · 85% confidence The document is a Hong Kong Exchange announcement under Rule 13.09 and Part XIVA of the SFO providing principal unaudited financial data for the nine months ended 30 September 2025. It contains key highlights (revenue, profit, cash flow, assets, equity) rather than a full interim report. This matches an initial periodic financial results announcement (Earnings Release). 9M 2025
2025-10-23 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-10-23 English
ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE THIRD QUARTER OF 2025
Earnings Release Classification · 90% confidence The document is a brief announcement under HKEx Listing Rule 13.09 providing the principal unaudited accounting data and financial indicators for the third quarter. It contains only key financial highlights (revenue, net profit, EPS, assets) and is not a full interim/quarterly report with notes or management discussion. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results, key highlights only). Q3 2025
2025-10-21 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-10-21 English
ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025
Earnings Release Classification · 91% confidence The document is an exchange announcement under HKSE Listing Rule 13.09 providing preliminary unaudited financial data (key highlights only) for the nine months ended 30 September 2025. It contains summary revenue, profit, EPS and segment commentary, but is not a full interim/quarterly report. This aligns with an initial earnings release rather than a comprehensive interim report or other filing. Hence, it is classified as an Earnings Release (ER). 9M 2025
2025-10-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.